Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®

NCT00435812 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.

NCT NCT00435812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®
Lead sponsor
Dynavax Technologies Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2008
Enrollment
2,428 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b